A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)

NCT02714608 Phase 2 UNKNOWN

Ginsenoside H dripping pills is a kind of traditional Chinese medicine(TCM), This study is being conducted to evaluate the efficacy and safety of ginsenoside H dripping pills in patients with advanced (stage ⅢB/Ⅳ) Non-small Cell Lung Cancer (Syndrome Of Qi-Deficiency) and explore the optimal dosage

Details

Lead sponsor	Tasly Pharmaceuticals, Inc.
Phase	Phase 2
Status	UNKNOWN
Enrolment	144
Start date	2016-05
Completion	2018-12

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Interventions

• Ginsenoside H dripping pills
• Ginsenoside H dripping pills+Placebo
• Placebo

Primary outcomes

• Progression-free survival (PFS) — through study completion, an average of 1 year
  Evaluate progression free survival (PFS) in the 3 groups : 0 , every 8 weeks and the end of treatment

Countries

China